Duration of Dual Antiplatelet Therapy After Coronary Stenting

Author(s): Gerasimos Siasos, Konstantinos Mourouzis, Evangelos Oikonomou, Manolis Vavuranakis, Georgia Vogiatzi, Alexandros Briasoulis, Nikolaos Papageorgiou, Theodore G. Papaioannou, Thodoris Zografos, Angeliki Papapanagiotou, Athanasios G. Papavassiliou, Christodoulos Stefanadis, Dimitris Tousoulis.

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 29 , 2016

Submit Manuscript
Submit Proposal

Abstract:

Background: Dual antiplatelet therapy (DAPT) is one of the cornerstones of coronary artery disease (CAD) treatment. Standard DAPT requires one of, P2Y12 receptor inhibitors, clopidogrel, prasugrel or ticagrelor as an adjunct therapy to aspirin administration. The decision over DAPT duration depends on the evaluation of thrombotic risk and the assessment of the probability for major bleeding events. Methods: The goal of this work was to identify which would be the appropriate combination of antiplatelet agents and the optimal duration of DAPT, based on the patient’s medical history and clinical characteristics. A thorough search of PubMed and the Cochrane Database was conducted in order to identify randomized controlled trials, observational studies, current ESC and ACC/AHA guidelines and novel articles on the subject. Results: The decision over DAPT duration is based on a careful approach which requires the evaluation of thrombotic risk and the assessment of the probability for major bleeding events. A series of aspects and special conditions may influence the duration of DAPT after stenting e.g. the type of the implanted stent (DES or BMS) or if the commencement of DAPT is administered in the context of an acute coronary syndrome or in the setting of stable CAD. Current guidelines can assist clinicians in making decisions but treating patients in special groups e.g. with diabetes mellitus or the elderly people can be very demanding. Conclusion: Studies which examined optimal DAPT duration, displayed controversial results, mainly observed because of the discrepancy and heterogeneity between different study designs or the decision of a great proportion of investigators to statistically test for non-inferiority. A careful, patient-centered approach, which considers thrombotic risk versus the risk for bleeding complications and other individual characteristics and comorbidities, is required when deciding DAPT duration.

Keywords: Antiplatelet treatment, cardiovascular diseases, clopidogrel, coronary artery disease, percutaneous coronary intervention.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 22
ISSUE: 29
Year: 2016
Page: [4583 - 4595]
Pages: 13
DOI: 10.2174/1381612822666160720144139
Price: $58

Article Metrics

PDF: 24
HTML: 3